Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology
Strengthens Patent Portfolio Protecting Horsepox-Based Live Virus Vaccines
TNX-1840 and TNX-1850 are Potential RPV Vaccines Designed to Protect Against COVID-19
Confirms Leadership Position in Synthetic Biology
Statutory Term of New Patent Expected to Provide Exclusivity Until 2037
CHATHAM, N.J., June 01, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,345,896 to the Company on May 31, 2022. This patent, entitled “Synthetic Chimeric Poxviruses,” includes claims covering synthetic horsepox virus, the basis for the Company’s TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2. This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.
